Famar to buy Sanofi plant in Madrid

Published: 20-Jan-2011
Manufacturing Packaging Finance

Will extend its sterile dosage form manufacturing capabilities

Famar plans to acquire a sanofi-aventis plant in Madrid, Spain to expand its sterile dose manufacturing capabilities and capacity.

The Athens, Greece-based firm said it would integrate the plant into its network of 11 pharmaceutical production sites across Europe, which includes distribution centres in France, Greece, Italy and The Netherlands.

The network provides development, manufacturing, packaging and logistics services for all dosage forms.

All employees at the Avenida de Leganes plant in Alcorcon, Madrid will be transferred to Famar.

The company said the plant, which produces solid and sterile forms including freeze drying, and currently supplies more than 50 markets, will provide a solid platform from which to develop its services.

The acquisition of the plant is also an opportunity for Famar to strengthen its ties with sanofi-aventis, originally made when the company acquired a plant in L’Aigle, France from the French drugmaker in 2001.

Famar also acquired a plant at Saint-Remy in France from Abbott in 2007, which is integrated to the L’Aigle business unit and has been developed as a centre for sterile and lyophilised production.

Once the deal has been finalised, sanofi-aventis will continue to source certain products from the site.

Famar said it has a ‘significant investment plan’ to expand the sterile capacities and services at the plant.

The transaction should be completed by the end of the second quarter.

  • Companies:
  • Famar
  • Sanofi
See more

You may also like

Manufacturing

Sanofi opens €558m modular vaccine and biologics manufacturing facility in Singapore

Read more
The biopharmaceutical manufacturing facility will allow Sanofi to manufacture up to four vaccines and biologic medicines simultaneously, while also enhancing the area's biopharma supply chain

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. TekniPlex Healthcare to showcase expanded capacity and sustainability solutions at Pharmapack Company highlights EU-based advancements in injection blow molding, multilayer blown films, and sustainable blister packaging
  4. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Sanofi opens €558m modular vaccine and biologics manufacturing facility in Singapore

The biopharmaceutical manufacturing facility will allow Sanofi to manufacture up to four vaccines and biologic medicines simultaneously, while also enhancing the area's biopharma supply chain
Manufacturing

Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site

The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
Finance

Sanofi begins negotiations with CD&R to sell stake in Opella

Opella is currently estimated to be worth €16bn, and CD&R's stake will allow the consumer healthcare company to grow as a standalone business
Manufacturing

Implementing advanced manufacturing technologies for novel therapies

Michele Ghinizzini, Senior Vice President, Global Head of Engineering and Maintenance at Sanofi, explores the elements that enable the realistic implementation of advanced technologies in drug development and manufacturing
Finance

Sanofi finalises Inhibrx acquisition

The acquisition expands Sanofi’s AATD therapeutic pipeline
Manufacturing

Sanofi and Novavax co-commercialise COVID-19 vaccine

The agreement will aim to commercialise Novavax's adjuvanted COVID-19 vaccination globally, as well as develop a COVID-19 and flu combination vaccine
Drug Delivery

Sanofi pledges to sell over €10bn in vaccine sales

In less than two years, Sanofi has delivered a competitive mRNA platform with improved potency and thermostability that performs with both viral and bacterial targets
Subscribe now